摘要
目的研究FZD7与β-catenin在不同亚型乳腺癌中的临床表达意义,分析两者间的关系。方法随机选取2015年2月-2016年2月在该院接受治疗的乳腺癌患者48例,分为三阴乳腺癌组11例和非三阴乳腺癌组37例。采用免疫组化染色法观察两组患者FZD7与β-catenin的表达情况。结果癌旁正常组织中未见FZD7表达,β-catenin只在乳腺和腺泡上皮细胞中表达。乳腺癌组织中FZD7在细胞膜上表达,三阴乳腺癌的阳性表达率为63.6%,非三阴乳腺癌的阳性表达率为43.2%。非三阴乳腺癌FZD7的阳性表达率较三阴性乳腺癌低(P<0.05);β-catenin在细胞膜上表达较弱,也会在细胞质和细胞核中表达。三阴乳腺癌正常表达率72.7%,非三阴乳腺癌的正常表达率为60.0%。三阴乳腺癌β-catenin异常表达率高于非三阴乳腺癌(P<0.05)结论 FZD7阳性表达,β-catenin异常表达及淋巴结转移是不同亚型乳腺癌患者的独立预后影响因素。
Objective To research the clinical expressions and significance of FZD7 and β-catenin in different subtypes of breast cancer, analyze the interrelationship. Methods From February 2015 to February 2016, 48 breast cancer patients treated in the 98th Hospital of PLA were randomly selected and divided into triple negative breast cancer group (11 patients) and non-triple negative breast cancer group (37 patients ) . Immunohistochemical staining was used to observe the expressions of FZD7 and β- eatenin in the two groups. Results FZD7 did not express in normal paracaneerous tissue, β-catenin only expressed in mammary epithelial cells and aeinar epithelial ceils. FZD7 was located in cell membrane of breast cancer tissue. The positive expression rates in triple negative breast cancer group and non-triple negative breast cancer group were 63.6% and 43.2% , respectively. The positive expression rate of FZD7 in non-triple negative breast cancer group was statistically significantly lower than that in triple negative breast cancer group ( P〈0. 05 ) . The expression of β- eatenin in cell membrane was weak, β-eatenin also expressed in cytoplasm and cell nucleus. The normal expression rates in triple negative breast cancer group and non-triple negative breast cancer group were 72. 7% and 60. 0% , respectively. The normal expression rate in triple negative breast cancer group was statistically significantly higher than that in non-triple negative breast cancer group ( P〈0. 05 ) . Conclusion Positive expression of FZDT, abnormal expression of β-catenin, and lymph node metastasis are independent influencing factors of prognosis of patients with different subtypes of breast cancer.
作者
单浩
沈娟
盛以泉
沈海英
SHAN Hao;SHEN Juan;SHENG Yi-Quan;et al.(Department of Clinical Laboratory, the 98th Hospital of PLA, Huzhou, Zhejiang 313000, China)
出处
《中国妇幼保健》
CAS
2018年第13期2942-2944,共3页
Maternal and Child Health Care of China